These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 16377145)

  • 1. Historical data in the design and interpretation of trials with newly diagnosed patients.
    Baulac M
    Epilepsy Res; 2006 Jan; 68(1):77-81. PubMed ID: 16377145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Historical control withdrawal to monotherapy.
    French J
    Epilepsy Res; 2006 Jan; 68(1):74-7. PubMed ID: 16377146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Historical control monotherapy design in the treatment of epilepsy.
    French JA; Wang S; Warnock B; Temkin N
    Epilepsia; 2010 Oct; 51(10):1936-43. PubMed ID: 20561024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. When clinical trials make history: demonstrating efficacy of new antiepileptic drugs as monotherapy.
    Perucca E
    Epilepsia; 2010 Oct; 51(10):1933-5. PubMed ID: 20491875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monotherapy clinical trial design.
    Sachdeo R
    Neurology; 2007 Dec; 69(24 Suppl 3):S23-7. PubMed ID: 18071154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Choice of delta noninferiority margin and dependency of the noninferiority trials.
    Tsong Y; Zhang J; Levenson M
    J Biopharm Stat; 2007; 17(2):279-88. PubMed ID: 17365224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A note on the conservativeness of the confidence interval approach for the selection of non-inferiority margin in the two-arm active-control trial.
    Sankoh AJ
    Stat Med; 2008 Aug; 27(19):3732-42. PubMed ID: 18407575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Starting and stopping treatment for seizures and epilepsy.
    Chadwick D
    Epilepsia; 2006; 47 Suppl 1():58-61. PubMed ID: 17044828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statistical issues on objective, design, and analysis of noninferiority active-controlled clinical trial.
    Tsong Y; Wang SJ; Hung HM; Cui L
    J Biopharm Stat; 2003 Feb; 13(1):29-41. PubMed ID: 12635901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the cognitive effects of tiagabine and carbamazepine as monotherapy in newly diagnosed adult patients with partial epilepsy: pooled analysis of two long-term, randomized, follow-up studies.
    Aikiä M; Jutila L; Salmenperä T; Mervaala E; Kälviäinen R
    Epilepsia; 2006 Jul; 47(7):1121-7. PubMed ID: 16886974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Issues with statistical risks for testing methods in noninferiority trial without a placebo ARM.
    Hung HM; Wang SJ; O'Neill R
    J Biopharm Stat; 2007; 17(2):201-13. PubMed ID: 17365218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous test for superiority and noninferiority hypotheses in active-controlled clinical trials.
    Tsong Y; Zhang J
    J Biopharm Stat; 2007; 17(2):247-57. PubMed ID: 17365221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Designing clinical trials to assess antiepileptic drugs as monotherapy : difficulties and solutions.
    Perucca E
    CNS Drugs; 2008; 22(11):917-38. PubMed ID: 18840033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Active-controlled, non-inferiority trials in oncology: arbitrary limits, infeasible sample sizes and uninformative data analysis. is there another way?
    Carroll KJ
    Pharm Stat; 2006; 5(4):283-93. PubMed ID: 17128427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal design of clinical trials comparing several treatments with a control.
    Marschner IC
    Pharm Stat; 2007; 6(1):23-33. PubMed ID: 17323312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Control theory: placebo-controlled drug trials have problems. Active-controlled drug trials are not always the solution.
    Golomb BA
    Am J Bioeth; 2009 Sep; 9(9):67-9. PubMed ID: 19998203
    [No Abstract]   [Full Text] [Related]  

  • 17. A two-stage sample size recalculation procedure for placebo- and active-controlled non-inferiority trials.
    Schwartz TA; Denne JS
    Stat Med; 2006 Oct; 25(19):3396-406. PubMed ID: 16900573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A covariate-adjustment regression model approach to noninferiority margin definition.
    Nie L; Soon G
    Stat Med; 2010 May; 29(10):1107-13. PubMed ID: 20209669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can we eliminate placebo in ALS clinical Trials?
    Simmons Z
    Muscle Nerve; 2009 Jun; 39(6):861-5. PubMed ID: 19382170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cognitive and psychomotor effects of remacemide and carbamazepine in newly diagnosed epilepsy.
    Wesnes KA; Edgar C; Dean AD; Wroe SJ
    Epilepsy Behav; 2009 Mar; 14(3):522-8. PubMed ID: 19111629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.